CORRELATION OF DIABETES REMISSION WITH REDUCTIONS IN BLOOD PRESSURE AND CARDIOVASCULAR RISK SCORES: RESULTS OF SIX MONTHS OF RANDOMISED TRIAL WITH DIGITAL TWIN TECHNOLOGY. (June 2022)
- Record Type:
- Journal Article
- Title:
- CORRELATION OF DIABETES REMISSION WITH REDUCTIONS IN BLOOD PRESSURE AND CARDIOVASCULAR RISK SCORES: RESULTS OF SIX MONTHS OF RANDOMISED TRIAL WITH DIGITAL TWIN TECHNOLOGY. (June 2022)
- Main Title:
- CORRELATION OF DIABETES REMISSION WITH REDUCTIONS IN BLOOD PRESSURE AND CARDIOVASCULAR RISK SCORES: RESULTS OF SIX MONTHS OF RANDOMISED TRIAL WITH DIGITAL TWIN TECHNOLOGY
- Authors:
- Shamanna, Paramesh
Joshi, Shashank
Shah, Lisa
Dharmalingam, Mala
Vadavi, Arun
Damodaran, Suresh
Mohammed, Jahangir
Mohamed, Maluk
Poon, Terrence
Keshavamurthy, Ashok
Thajudeen, Mohamed
Bhonsley, Suchitra - Abstract:
- Abstract : Objective: Twin precision treatment improves metabolic parameters using a whole-body digital twin platform powered by artificial intelligence and internet of things Design and method: We evaluated 6 month data of RCCT (n = 128). Diabetes remission was defined as HbA1c < 6.5% for at least 3 months without Anti-Diabetic Medication (ADM) Results: Mean age and duration of diabetes (yrs) was 43 (±9.4, 95% CI 42 to 45) and 3.5 (±2.7, 95% CI 3 to 4). 88.3% (n = 113) achieved diabetes remission. At enrolment 76% (n = 97) were on ADM, of which 90% (n = 87) were off ADM. There was a significant change (change, % reduction) in HbA1c % (8.9 to 5.6, -38.2), SBP mmHg (128 to 118, -8.5), DBP mmHg (84 to 78, -7.8), waist circumference cm (97 to 86, -11.2), body weight kg (78 to 67, -12.7), BMI (27.2 to 23.5, -13.6), HOMA2IR (1.9 to 1.02, -48.4), Framingham Risk Score (FRS) (15.4 to 6.6, -56.4), Atherosclerotic Cardiovascular Disease (ASCVD) (7.9 to 3.1, -60.7), [p < 0.0001], QRISK3 (12.8 to 9.3, -27.3) scores, [p = 0.0027], at six months. (Table). There was a significant positive correlation between HbA1c reduction, and reductions in SBP (r 0.2, 95% CI 0.03 to 0.36, p = 0.03), HOMA2IR (r 0.23, 95% CI 0.06 to 0.39, p = 0.0074), ASCVD (r -0.17, 95% CI 0.004 to 0.34, p = 0.04), FRS (r 0.22, 95% CI 0.056 to 0.38, p = 0.0097). 57% (n = 73) were hypertensives. At 6 month, 33% (n = 6/18) were off anti-hypertensive medication Conclusions: Digital twin technology enables a significantAbstract : Objective: Twin precision treatment improves metabolic parameters using a whole-body digital twin platform powered by artificial intelligence and internet of things Design and method: We evaluated 6 month data of RCCT (n = 128). Diabetes remission was defined as HbA1c < 6.5% for at least 3 months without Anti-Diabetic Medication (ADM) Results: Mean age and duration of diabetes (yrs) was 43 (±9.4, 95% CI 42 to 45) and 3.5 (±2.7, 95% CI 3 to 4). 88.3% (n = 113) achieved diabetes remission. At enrolment 76% (n = 97) were on ADM, of which 90% (n = 87) were off ADM. There was a significant change (change, % reduction) in HbA1c % (8.9 to 5.6, -38.2), SBP mmHg (128 to 118, -8.5), DBP mmHg (84 to 78, -7.8), waist circumference cm (97 to 86, -11.2), body weight kg (78 to 67, -12.7), BMI (27.2 to 23.5, -13.6), HOMA2IR (1.9 to 1.02, -48.4), Framingham Risk Score (FRS) (15.4 to 6.6, -56.4), Atherosclerotic Cardiovascular Disease (ASCVD) (7.9 to 3.1, -60.7), [p < 0.0001], QRISK3 (12.8 to 9.3, -27.3) scores, [p = 0.0027], at six months. (Table). There was a significant positive correlation between HbA1c reduction, and reductions in SBP (r 0.2, 95% CI 0.03 to 0.36, p = 0.03), HOMA2IR (r 0.23, 95% CI 0.06 to 0.39, p = 0.0074), ASCVD (r -0.17, 95% CI 0.004 to 0.34, p = 0.04), FRS (r 0.22, 95% CI 0.056 to 0.38, p = 0.0097). 57% (n = 73) were hypertensives. At 6 month, 33% (n = 6/18) were off anti-hypertensive medication Conclusions: Digital twin technology enables a significant reduction in BP, CV risk scores and insulin resistance which correlates with the remission of T2DM … (more)
- Is Part Of:
- Journal of hypertension. Volume 40(2022)Supplement 1
- Journal:
- Journal of hypertension
- Issue:
- Volume 40(2022)Supplement 1
- Issue Display:
- Volume 40, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 40
- Issue:
- 1
- Issue Sort Value:
- 2022-0040-0001-0000
- Page Start:
- e75
- Page End:
- e76
- Publication Date:
- 2022-06
- Subjects:
- Hypertension -- Periodicals
Hypertension -- Periodicals
616.132005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://journals.lww.com/jhypertension/pages/default.aspx ↗
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00004872-000000000-00000 ↗
http://www.jhypertension.com/ ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/01.hjh.0000835932.52938.30 ↗
- Languages:
- English
- ISSNs:
- 1473-5598
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5004.510000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21969.xml